T₂-weighted combined with diffusion-weighted images for evaluating prostatic transition zone tumors at 3 Tesla

References

• 1  Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin.61(2),69–90 (2011).
  MedlineGoogle Scholar
• 2  Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E. Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J. Clin. Oncol.28(10),1714–1720 (2010).
  MedlineGoogle Scholar
• 3  Bianco FJ Jr, Mchone BR, Wagner K et al. Prevalence of erectile dysfunction in men screened for prostate cancer. Urology74(1),89–93 (2009).
  MedlineGoogle Scholar
• 4  Portalez D, Rollin G, Leandri P et al. Prospective comparison of T₂W-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. Eur. Radiol.20(12),2781–2790 (2010).
  MedlineGoogle Scholar
• 5  De Visschere P, Oosterlinck W, De Meerleer G, Villeirs G. Clinical and imaging tools in the early diagnosis of prostate cancer, a review. JBR–BTR93(2),62–70 (2010).
  Medline CASGoogle Scholar
• 6  Grignon DJ, Sakr WA. Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland? J. Cell. Biochem. Suppl.19,267–269 (1994).
  Medline CASGoogle Scholar
• 7  Elliott CS, Shinghal R, Presti JC Jr. Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes. J. Urol.180(4),1318–1323; discussion 1323–1324 (2008).
  MedlineGoogle Scholar
• 8  Swindle P, Ramadan S, Stanwell P, McCredie S, Russell P, Mountford C. Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology. Magma21(6),423–434 (2008).
  Medline CASGoogle Scholar
• 9  Bostwick DG. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer78(2),330–336 (1996).
  Medline CASGoogle Scholar
• 10  Afaq A, Andreou A, Koh DM. Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how? Cancer Imaging10(10),S179–S188 (2010).
  MedlineGoogle Scholar
• 11  Jacobs MA, Ouwerkerk R, Petrowski K, Macura KJ. Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. Top. Magn. Reson. Imaging19(6),261–272 (2008).
  MedlineGoogle Scholar
• 12  Kim CK, Park BK, Park W, Kim SS. Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom. Imaging35(2),246–252 (2010).
  MedlineGoogle Scholar
• 13  Kumar V, Jagannathan NR, Kumar R et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn. Reson. Imaging24(5),541–548 (2006).
  Medline CASGoogle Scholar
• 14  Lee KC, Bradley DA, Hussain M et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia9(12),1003–1011 (2007).
  MedlineGoogle Scholar
• 15  Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T₂-weighted images for detection – a multireader study. Radiology250(1),145–151 (2009).
  MedlineGoogle Scholar
• 16  Charles-Edwards EM, Desouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging6,135–143 (2006).
  MedlineGoogle Scholar
• 17  Fradet V, Kurhanewicz J, Cowan JE et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology256(1),176–183 (2010).
  MedlineGoogle Scholar
• 18  De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am. J. Roentgenol.194(6),1427–1433 (2010).
  MedlineGoogle Scholar
• 19  Li H, Sugimura K, Kaji Y et al. Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am. J. Roentgenol.186(3),729–742 (2006).
  MedlineGoogle Scholar
• 20  Akin O, Sala E, Moskowitz CS et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology239(3),784–792 (2006).
  MedlineGoogle Scholar
• 21  Haider MA, Van Der Kwast TH, Tanguay J et al. Combined T₂-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am. J. Roentgenol.189(2),323–328 (2007).
  MedlineGoogle Scholar
• 22  Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 tesla. Invest. Radiol.41(2),185–188 (2006).
  MedlineGoogle Scholar
• 23  Ohno Y, Hatabu H, Takenaka D et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology231(3),872–879 (2004).
  MedlineGoogle Scholar
• 24  Onishi Y, Ohno Y, Koyama H et al. Non-small cell carcinoma: comparison of postoperative intra- and extrathoracic recurrence assessment capability of qualitatively and/or quantitatively assessed FDG–PET/CT and standard radiological examinations. Eur. J. Radiol.79(3),473–479 (2011).
  MedlineGoogle Scholar
• 25  Wang Z, Chang YC. Marker selection via maximizing the partial area under the ROC curve of linear risk scores. Biostatistics12(2),369–385 (2011).
  Medline CASGoogle Scholar
• 26  Ellis JH, Tempany C, Sarin MS, Gatsonis C, Rifkin MD, McNeil BJ. MR imaging and sonography of early prostatic cancer: pathologic and imaging features that influence identification and diagnosis. AJR Am. J. Roentgenol.162(4),865–872 (1994).
  Medline CASGoogle Scholar
• 27  Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T₂-weighted imaging. J. Magn. Reson. Imaging31(3),625–631 (2010).
  MedlineGoogle Scholar
• 28  Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0 T. J. Magn. Reson. Imaging23(2),130–134 (2006).
  MedlineGoogle Scholar
• 29  Tamada T, Sone T, Jo Y et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J. Magn. Reson. Imaging28(3),720–726 (2008).
  MedlineGoogle Scholar
• 30  Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MR imaging of the prostate in clinical practice. Magma21(6),379–392 (2008).
  MedlineGoogle Scholar